GI
ARCT icon

GAMMA Investing’s Arcturus Therapeutics ARCT Stock Holding History

GAMMA Investing’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8K Buy
1,750
+244
+16% +$1.92K ﹤0.01% 3127
2026
Q1 		$11.6K Buy
1,506
+1,044
+226% +$7.62K ﹤0.01% 2995
2025
Q4 		$2.83K Sell
462
-162
-26% -$1.75K ﹤0.01% 3500
2025
Q3 		$11.5K Buy
624
+43
+7% +$691 ﹤0.01% 2817
2025
Q2 		$7.56K Buy
581
+87
+18% +$1.03K ﹤0.01% 2950
2025
Q1 		$5.23K Buy
494
+348
+238% +$5.52K ﹤0.01% 3070
2024
Q4 		$2.48K Buy
146
+29
+25% +$546 ﹤0.01% 3157
2024
Q3 		$2.72K Sell
117
-61
-34% -$1.3K ﹤0.01% 2968
2024
Q2 		$4.33K Buy
178
+124
+230% +$3.76K ﹤0.01% 2636
2024
Q1 		$1.82K Buy
54
+5
+10% +$177 ﹤0.01% 2774
2023
Q4 		$1.62K Buy
+49
New +$1.17K ﹤0.01% 2648

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GAMMA Investing's ARCT Position: Q2 2026 in Review

GAMMA Investing increased its Arcturus Therapeutics (ARCT) stake by 16% in Q2 2026, buying an estimated $1.92K and bringing the position to 1,750 shares worth $11.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3127.

GAMMA Investing first reported a position in ARCT in Q4 2023 and has held it in 11 quarters since. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • GAMMA Investing held 1,750 shares of Arcturus Therapeutics worth $11.8K as of Q2 2026.
  • GAMMA Investing bought 244 Arcturus Therapeutics shares in Q2 2026, an estimated $1.92K.
  • Arcturus Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3127 holding.
  • GAMMA Investing first reported a position in Arcturus Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.